The rapid efficacy of abatacept in a patient with rheumatoid vasculitis
详细信息 查看全文
- 作者：Wataru Fujii (1)
Masataka Kohno (1)
Hidetaka Ishino (1)
Amane Nakabayashi (1)
Kazuki Fujioka (1)
Takashi Kida (1)
Hidetake Nagahara (1)
Ken Murakami (1)
Kaoru Nakamura (1)
Takahiro Seno (1)
Aihiro Yamamoto (1)
Yutaka Kawahito (1) kawahity@koto.kpu-m.ac.jp - 关键词：Abatacept – ; Cytotoxic T lymphocyte ; associated antigen 4 (CTLA4) – ; Rheumatoid vasculitis
- 刊名：Modern Rheumatology
- 出版年：2012
- 出版时间：August 2012
- 年：2012
- 卷：22
- 期：4
- 页码：630-634
- 全文大小：375.3 KB
- 参考文献：1. Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med. 1984;76:377–84.
2. Breedveld FC. Vasculitis associated with connective tissue disease. Baillieres Clin Rheumatol. 1997;11:315–34.
3. Abel T, Andrews BS, Cunningham PH, Brunner CM, Davis JS, Horwitz DA, et al. Rheumatoid vasculitis: effect of cyclophosphamide on the clinical course and levels of circulating immune complexes. Ann Intern Med. 1980;93:407–13.
4. Unger L, Kayser M, N眉sslein HG. Successful treatment of severe rheumatoid vasculitis by infliximab. Ann Rheum Dis. 2003;62:587–8.
5. van der Bijl AE, Allaart CF, Van Vugt J, Van Duinen S, Breedveld FC. Rheumatoid vasculitis treated with infliximab. J Rheumatol. 2005;32:1607–9.
6. Garcia-Porrua C, Gonzalez-Gay MA, Quevedo V. Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis? J Rheumatol. 2006;33:433–4.
7. Genant HK, Peterfy CG, Westhovens R, Becker JC, Aranda R, Vratsanos G, et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: result from the long-term extension of the AIM trial. Ann Rheum Dis. 2008;67:1084–9.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
9. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140:659–62.
10. Schmid FR, Cooper NS, Ziff M, McEwen C. Arteritis in rheumatoid arthritis. Am J Med. 1961;30:56–83.
11. Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol. 2004;33:65–72.
12. Genta MS, Genta RM, Gabay C. Systemic rheumatoid vasculitis: a review. Semin Arthritis Rheum. 2006;36:88–98.
13. Vollertsen RS, Conn DL. Vasculitis associated with rheumatoid arthritis. Rheum Dis Clin North Am. 1990;16:445–61.
14. Scott DG, Bacon PA, Tribe CR. Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine (Baltimore). 1981;60:288–97.
15. Salama AK, Hodi FS. Cytotoxic T-lymphocyte–associated antigen-4. Clin Cancer Res. 2011;17:4622–8.
16. Fiocco U, Sfriso P, Oliviero F, Pagnin E, Scagliori E, Campana C, et al. Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept. Autoimmun Rev. 2008;8:76–82.
17. Yen JH, Moore BE, Nakajima T, Scholl D, Schaid DJ, Weyand CM, et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med. 2001;193:1159–67.
18. Csernok E, Trabandt A, M眉ller A, Wang GC, Moosig F, Paulsen J, et al. Cytokine profiles in Wegener’s granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum. 1999;42:742–50.
19. Jakiela B, Sanak M, Szczeklik W, Sokolowska B, Plutecka H, Mastalerz L, et al. Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol. 2011;29:S23–34.
20. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322:271–5.
21. Carr EJ, Niederer HA, Williams J, Harper L, Watts RA, Lyons PA, et al. Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis. BMC Med Genet. 2009;10:121.
22. Zhou Y, Huang D, Paris PL, Sauter CS, Prock KA, Hoffman GS. An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener’s granulomatosis. Arthritis Rheum. 2004;50:2645–50.
23. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221–32.
24. Maher LV, Wilson JG. Successful treatment of rheumatoid vasculitis-associated foot drop with rituximab. Rheumatology (Oxford). 2006;45:1450–1.
25. Hellmann M, Jung N, Owczarczyk K, Hallek M, Rubbert A. Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis. Rheumatology (Oxford). 2008;47:929–30.
26. Westhovems R, Kremer JM, Moreland LW, Emery P, Russell AS, Li T, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol. 2009;36:736–42. - 作者单位：1. Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto, 602-8566 Japan
- ISSN：1439-7609
文摘
We report a case of rheumatoid vasculitis (RV) that responded well to abatacept, a cytotoxic T lymphocyte-associated antigen 4 (CTLA4)-immunoglobulin fusion protein. A 38-year-old woman developed RV despite treatment with methotrexate and tumor necrosis factor (TNF) inhibitors. The effects of steroid therapy, immunoabsorption plasmapheresis, and interleukin-6 inhibitor were insufficient, however, administration of abatacept rapidly improved her clinical symptoms with almost normalization of the immunological findings. This is the first published case report of the successful treatment of RV with abatacept.